Initia is pleased to announce that Dr. Iurie Arian and his research team presented three clinical studies at the 27th World Meeting on Sexual Medicine (WMSM), held in Porto, Portugal, February 25–28, 2026.
The World Meeting on Sexual Medicine (WMSM) is one of the leading global scientific conferences in the field of urology and sexual medicine, bringing together international experts to share the latest research on erectile dysfunction (ED), Peyronie’s disease, and other male sexual health conditions.
The studies presented by Dr. Arian’s team focused on Low-Intensity Extracorporeal Shockwave Therapy (LiESWT) using the Morenova® shockwave system, exploring innovative treatment protocols designed to improve outcomes for patients with vasculogenic erectile dysfunction and Peyronie’s disease associated with ED.
Advancing Shockwave Therapy Protocols for Erectile Dysfunction
The first study investigated whether micro-dose intracavernosal alprostadil administration prior to LiESWT could enhance treatment outcomes in men with vasculogenic erectile dysfunction.
The research demonstrated significant improvements in erectile function and penile hemodynamics. After three months of follow-up:
- The International Index of Erectile Function (IIEF-EF) score increased from 15.8 to 22.8, representing an improvement of approximately 44%.
- Erection Hardness Score (EHS) improved from 2.4 to 3.5, indicating stronger erectile rigidity.
- Penile Doppler ultrasound measurements showed improved vascular parameters, including increased peak systolic velocity (PSV) and decreased end-diastolic velocity (EDV).
These findings suggest that pharmacologic priming before shockwave therapy may improve cavernosal perfusion and optimize energy delivery, potentially enhancing the regenerative effects of LiESWT.
Multi-Zonal Shockwave Therapy for Vasculogenic Erectile Dysfunction
The second study evaluated a condensed multi-zonal LiESWT treatment protocol, in which shockwave therapy was applied to multiple anatomical regions of the penis, including the penile root, shaft, and dorsal neurovascular bundle.
In this prospective study of 84 men with mild-to-moderate vasculogenic erectile dysfunction, patients underwent six consecutive daily shockwave therapy sessions using the Morenova® system.
Key outcomes after three months included:
- 68% of patients achieved clinically meaningful improvement in erectile function, defined as a ≥4-point increase in IIEF-EF score.
- Average IIEF-EF scores improved from 15.6 to 21.1.
- Erection Hardness Score increased from 2.4 to 3.3.
- Penile Doppler parameters improved significantly, with PSV increasing and EDV decreasing, reflecting improved penile blood flow.
- 86% of patients reported improved satisfaction with PDE5 inhibitor therapy following LiESWT.
The study suggests that sequential multi-zonal treatment protocols may enhance vascular regeneration and functional recovery, supporting the role of LiESWT as a restorative therapy for vasculogenic erectile dysfunction.
Shockwave Therapy Combined with Multimodal Treatment for Peyronie’s Disease
The third study explored the use of LiESWT combined with multimodal pharmacologic therapy in men with stable Peyronie’s disease (PD) and erectile dysfunction.
In this prospective study of 32 patients, shockwave therapy using both linear and focal applicators was combined with adjunctive medical treatment, including tadalafil, L-arginine with Pycnogenol, and potassium para-aminobenzoate (POTABA). Patients with hypogonadism also received testosterone supplementation.
After six months of follow-up:
- 91% of patients demonstrated improvement in erectile function.
- Mean IIEF-EF scores increased from 15.9 to 22.8.
- Erection Hardness Score improved from 2.4 to 3.5.
- 36% of patients experienced measurable penile curvature reduction (8–12°).
- 56% reported plaque softening and improved penile elasticity.
- 38% discontinued PDE5 inhibitor therapy due to restored spontaneous erections.
These results highlight the potential of integrating shockwave therapy with multimodal medical treatment to address both the structural and functional components of Peyronie’s disease.
Supporting Clinical Research in Shockwave Therapy
The three studies presented at WMSM 2026 contribute to the growing body of evidence supporting Low-Intensity Extracorporeal Shockwave Therapy as a regenerative treatment for erectile dysfunction and related conditions.
By exploring optimized treatment protocols and combination therapies, the research further advances the understanding of how shockwave therapy can promote angiogenesis, improve penile hemodynamics, and restore erectile function.
All three studies were conducted using the Morenova® shockwave therapy system, a platform designed for clinical research and therapeutic innovation in sexual medicine and urology.
More scientific publications and clinical studies using the Morenova® system are available in the Initia Clinical Data Center.